Evidence map›Paper›PMID 29557730›Full record

ReviewNucleus (Austin, Tex.)2018

Invertebrate models of lamin diseases.

Ryszard Rzepecki, Yosef Gruenbaum

Open access · goldAbstract readReview
In one paragraph

Review in Nucleus (Austin, Tex.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Cells · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Use of Farnesyl Transferase Inhibitors in an Ageing Model inJournal of developmental biology · 2023
    Article
  8. Article
  9. Review
  10. Effects of mutant lamins on nucleo-cytoskeletal coupling inFrontiers in cell and developmental biology · 2022
    Article
  11. Article
  12. Article
  13. Laminopathies: what can humans learn from fruit flies.Cellular & molecular biology letters · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Ryszard Rzepeckia Laboratory of Nuclear Proteins, Faculty of Biotechnology , University of Wroclaw , Fryderyka Joliot-Curie, Wroclaw , Poland.
Yosef Gruenbauma Laboratory of Nuclear Proteins, Faculty of Biotechnology , University of Wroclaw , Fryderyka Joliot-Curie, Wroclaw , Poland.
University of Wrocław · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lamins are evolutionarily conserved nuclear intermediate filament proteins. They provide structural support for the nucleus and help regulate many other nuclear activities. Mutations in human lamin genes, and especially in the LMNA gene, cause numerous diseases, termed laminopathies, including muscle, cardiac, metabolic, neuronal and early aging diseases. Most laminopathies arise from autosomal dominant missense mutations. Many of the mutant residues are conserved in the lamin genes of the nematode Caenorhabditis elegans and the fruit fly Drosophila melanogaster. Our current understanding of the mechanisms leading to these diseases is mostly based on patients cell lines and animal models including C. elegans and D. melanogaster. The simpler lamin system and the powerful genetic tools offered by these invertebrate organisms greatly contributed to such studies. Here we provide an overview of the studies of laminopathies in Drosophila and C. elegans models.

Indexed as

Disease Models, AnimalAnimalsCaenorhabditis elegansDrosophila melanogasterHumansLaminsMusculoskeletal DiseasesMutationLaminsCaenorhabditis elegansDrosophilaEmery Dreifuss Muscular DystrophyLaminlaminopathiesnuclear envelopeprogeria

Identifiers

PMID29557730
PMCPMC5973256
OpenAlexW2794368602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.